Experts Predict FHLC Will Hit $81
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 07 2025
0mins
Should l Buy IRMD?
Source: NASDAQ.COM
Fidelity MSCI Health Care Index ETF Analysis: The Fidelity MSCI Health Care Index ETF (FHLC) has an implied analyst target price of $81.28, indicating a potential upside of 15.88% from its current trading price of $70.14.
Notable Holdings with Upside Potential: Key underlying holdings of FHLC, such as Xeris Biopharma Holdings (XERS), Mineralys Therapeutics (MLYS), and iRadimed Corp (IRMD), show significant upside potential based on analyst target prices, with XERS at 38.16% higher, MLYS at 21.59%, and IRMD at 17.06%.
Analyst Target Price Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets relative to current prices could lead to potential downgrades if they are based on outdated information.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of analysts' targets in light of recent developments in the companies and the healthcare industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IRMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IRMD
Wall Street analysts forecast IRMD stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 91.880
Low
98.00
Averages
99.00
High
100.00
Current: 91.880
Low
98.00
Averages
99.00
High
100.00
About IRMD
IRadimed Corporation develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and accessories and services. Its MRidium 3860+ MRI Compatible IV infusion pump system provides a non-magnetic Intravenous (IV) infusion pump system that is specifically designed for safe use during MRI procedures. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor with non-ferrous parts and other special features to deliver anesthesia safely and predictably and other IV medications or fluids during various MRI procedures. Its IRadimed 3880 MRI Compatible patient vital signs monitoring system has been designed with non-magnetic components and other features to monitor a patient’s vital signs safely and accurately during various MRI procedures. The Company sells its products primarily to hospitals and acute care facilities. The IRADIMED 3880 system operates dependably in magnetic fields up to 30,000 gauss.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Iradimed to Participate in 25th Annual Needham Virtual Healthcare Conference
- Conference Participation: Iradimed Corporation will participate in the 25th Annual Needham Virtual Healthcare Conference from April 13-16, 2026, where CFO Jack Glenn will hold one-on-one meetings with investors to enhance engagement and raise company visibility.
- Product Innovation: The MRidium® MRI-compatible IV infusion pump system developed by Iradimed is the only known non-magnetic infusion pump specifically designed for MRI procedures, enabling safe and reliable delivery of anesthesia and other IV fluids during scans, significantly reducing risks associated with traditional pumps.
- Monitoring System Advantages: The Iradimed 3880 MRI-compatible patient vital signs monitoring system operates reliably in magnetic fields up to 30,000 gauss, ensuring continuous monitoring of patient vital signs during MRI scans, thereby enhancing safety for critically ill patients and minimizing their time away from critical care units.
- Technical Features: This monitoring system includes features such as wireless ECG, wireless SpO2, non-magnetic respiratory CO2, and blood pressure monitoring, all designed for ease of use, effectively communicating patient vital signs to clinicians and improving clinical communication efficiency.
See More
Iradimed Corporation to Participate in 38th Annual Roth Conference
- Conference Participation: Iradimed Corporation will participate in the 38th Annual Roth Conference from March 22 to 24, 2026, at the Ritz-Carlton in Laguna Niguel, CA, where CEO Roger Susi and CFO Jack Glenn will hold one-on-one meetings with investors to strengthen relationships and showcase the company's innovative capabilities.
- Product Innovation: Iradimed is the only provider of a non-magnetic intravenous infusion pump system specifically designed for MRI procedures, enabling safe and reliable delivery of anesthesia and other IV fluids, significantly reducing common risks associated with MRI operations.
- Monitoring System Advantages: The Iradimed 3880 MRI-compatible patient vital signs monitoring system operates reliably in magnetic fields up to 30,000 gauss, ensuring continuous monitoring of patient vital signs during MRI scans, thereby enhancing the safety of critically ill patients.
- Technical Features: This monitoring system includes features such as wireless ECG, wireless SpO2, and non-magnetic respiratory CO2, with a compact and lightweight design that facilitates use during patient transfers, ensuring that critically ill patients remain in critical care units during MRI scans.
See More
IRadimed (IRMD.US) Officer Plans to Sell $9.87 Million in Common Stock via Form 144
Stock Sale Announcement: Officer Roger E. Susi intends to sell 100,000 shares of Iradimed's common stock on March 6, with a total market value of approximately $9.87 million.
Reduction in Shareholding: Since December 8, 2025, Roger E. Susi has reduced his shareholding in Iradimed by 40,000 shares, valued at approximately $3.92 million.
See More
Nine Ten Capital Management Sells IRadimed Shares Worth $29.42 Million
- Share Reduction Details: Nine Ten Capital Management sold 342,907 shares of IRadimed in Q4 2026, with an estimated trade value of $29.42 million, reflecting the impact of share price changes and the sale on its investment portfolio.
- Portfolio Adjustment: Following the sale, IRadimed now represents 13.2% of Nine Ten's 13F reportable assets, indicating a cautious approach to managing concentration risk within the fund's holdings.
- Strong Company Performance: IRadimed achieved its 18th consecutive quarter of record revenue in 2025, with Q4 sales reaching $22.7 million, a 17% year-over-year increase, showcasing its robust position in the MRI-compatible medical device market.
- Future Outlook: The company anticipates revenue of up to $96 million in 2026, with the broader rollout of the new 3870 MRI-compatible infusion pump expected to drive further growth, suggesting that long-term investors should focus on fundamentals despite the recent share reduction.
See More
Iradimed Reports Record Revenue for 18th Consecutive Quarter
- Sustained Revenue Growth: In Q4 2025, Iradimed achieved $22.7 million in revenue, a 17% increase from Q4 2024, marking the company's 18th consecutive quarter of record revenue, demonstrating its robust performance in the medical device market.
- Significant Net Income Rise: The company's non-GAAP net income reached $7 million, up 23% year-over-year, with earnings per share at $0.54, exceeding analyst expectations of $0.48, further solidifying investor confidence.
- Sales Driven by New Product: The launch of the 3870 intravenous infusion pump during the quarter boosted sales, indicating the company's innovative capabilities and effective response to market demand in MRI-compatible equipment.
- Dividend Increase: The company announced an increase in its quarterly dividend from $0.17 to $0.20 per share, effective March 6, reflecting financial health and confidence in future growth while enhancing shareholder returns.
See More
Iradimed Reports Record Revenue for 18th Consecutive Quarter
- Record Revenue: Iradimed achieved $22.7 million in revenue for Q4 2025, marking a 17% increase over Q4 2024, and setting a new all-time high for the 18th consecutive quarter, indicating robust growth in the medical device sector.
- Profit Exceeds Expectations: The company reported a non-GAAP net income of $7 million, translating to $0.54 per share, which surpassed the consensus analyst estimate of $0.48 by 12.5%, reflecting ongoing improvements in profitability.
- New Product Impact: The launch of the 3870 intravenous infusion pump during the quarter has strengthened Iradimed's competitive position in the MRI-compatible equipment market, which is expected to drive future sales growth.
- Dividend Increase: The company announced an increase in its quarterly dividend from $0.17 to $0.20 per share, effective March 6, demonstrating confidence in future cash flows and commitment to shareholder returns.
See More
Iradimed to Participate in 25th Annual Needham Virtual Healthcare Conference
- Conference Participation: Iradimed Corporation will participate in the 25th Annual Needham Virtual Healthcare Conference from April 13-16, 2026, where CFO Jack Glenn will hold one-on-one meetings with investors to enhance engagement and raise company visibility.
- Product Innovation: The MRidium® MRI-compatible IV infusion pump system developed by Iradimed is the only known non-magnetic infusion pump specifically designed for MRI procedures, enabling safe and reliable delivery of anesthesia and other IV fluids during scans, significantly reducing risks associated with traditional pumps.
- Monitoring System Advantages: The Iradimed 3880 MRI-compatible patient vital signs monitoring system operates reliably in magnetic fields up to 30,000 gauss, ensuring continuous monitoring of patient vital signs during MRI scans, thereby enhancing safety for critically ill patients and minimizing their time away from critical care units.
- Technical Features: This monitoring system includes features such as wireless ECG, wireless SpO2, non-magnetic respiratory CO2, and blood pressure monitoring, all designed for ease of use, effectively communicating patient vital signs to clinicians and improving clinical communication efficiency.
See More
Iradimed Corporation to Participate in 38th Annual Roth Conference
- Conference Participation: Iradimed Corporation will participate in the 38th Annual Roth Conference from March 22 to 24, 2026, at the Ritz-Carlton in Laguna Niguel, CA, where CEO Roger Susi and CFO Jack Glenn will hold one-on-one meetings with investors to strengthen relationships and showcase the company's innovative capabilities.
- Product Innovation: Iradimed is the only provider of a non-magnetic intravenous infusion pump system specifically designed for MRI procedures, enabling safe and reliable delivery of anesthesia and other IV fluids, significantly reducing common risks associated with MRI operations.
- Monitoring System Advantages: The Iradimed 3880 MRI-compatible patient vital signs monitoring system operates reliably in magnetic fields up to 30,000 gauss, ensuring continuous monitoring of patient vital signs during MRI scans, thereby enhancing the safety of critically ill patients.
- Technical Features: This monitoring system includes features such as wireless ECG, wireless SpO2, and non-magnetic respiratory CO2, with a compact and lightweight design that facilitates use during patient transfers, ensuring that critically ill patients remain in critical care units during MRI scans.
See More
IRadimed (IRMD.US) Officer Plans to Sell $9.87 Million in Common Stock via Form 144
Stock Sale Announcement: Officer Roger E. Susi intends to sell 100,000 shares of Iradimed's common stock on March 6, with a total market value of approximately $9.87 million.
Reduction in Shareholding: Since December 8, 2025, Roger E. Susi has reduced his shareholding in Iradimed by 40,000 shares, valued at approximately $3.92 million.
See More
Nine Ten Capital Management Sells IRadimed Shares Worth $29.42 Million
- Share Reduction Details: Nine Ten Capital Management sold 342,907 shares of IRadimed in Q4 2026, with an estimated trade value of $29.42 million, reflecting the impact of share price changes and the sale on its investment portfolio.
- Portfolio Adjustment: Following the sale, IRadimed now represents 13.2% of Nine Ten's 13F reportable assets, indicating a cautious approach to managing concentration risk within the fund's holdings.
- Strong Company Performance: IRadimed achieved its 18th consecutive quarter of record revenue in 2025, with Q4 sales reaching $22.7 million, a 17% year-over-year increase, showcasing its robust position in the MRI-compatible medical device market.
- Future Outlook: The company anticipates revenue of up to $96 million in 2026, with the broader rollout of the new 3870 MRI-compatible infusion pump expected to drive further growth, suggesting that long-term investors should focus on fundamentals despite the recent share reduction.
See More
Iradimed Reports Record Revenue for 18th Consecutive Quarter
- Sustained Revenue Growth: In Q4 2025, Iradimed achieved $22.7 million in revenue, a 17% increase from Q4 2024, marking the company's 18th consecutive quarter of record revenue, demonstrating its robust performance in the medical device market.
- Significant Net Income Rise: The company's non-GAAP net income reached $7 million, up 23% year-over-year, with earnings per share at $0.54, exceeding analyst expectations of $0.48, further solidifying investor confidence.
- Sales Driven by New Product: The launch of the 3870 intravenous infusion pump during the quarter boosted sales, indicating the company's innovative capabilities and effective response to market demand in MRI-compatible equipment.
- Dividend Increase: The company announced an increase in its quarterly dividend from $0.17 to $0.20 per share, effective March 6, reflecting financial health and confidence in future growth while enhancing shareholder returns.
See More
Iradimed Reports Record Revenue for 18th Consecutive Quarter
- Record Revenue: Iradimed achieved $22.7 million in revenue for Q4 2025, marking a 17% increase over Q4 2024, and setting a new all-time high for the 18th consecutive quarter, indicating robust growth in the medical device sector.
- Profit Exceeds Expectations: The company reported a non-GAAP net income of $7 million, translating to $0.54 per share, which surpassed the consensus analyst estimate of $0.48 by 12.5%, reflecting ongoing improvements in profitability.
- New Product Impact: The launch of the 3870 intravenous infusion pump during the quarter has strengthened Iradimed's competitive position in the MRI-compatible equipment market, which is expected to drive future sales growth.
- Dividend Increase: The company announced an increase in its quarterly dividend from $0.17 to $0.20 per share, effective March 6, demonstrating confidence in future cash flows and commitment to shareholder returns.
See More
